News Medical4d
Evaluating influenza vaccine ingredients
The influenza A virus genome consists of eight segments of single-stranded, negative-sense viral RNA, which encode multiple ...
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
The recombinant protein vaccine, dubbed GSK3943104, did not meet the study’s primary efficacy objective. GSK added that the ...
pharmaphorum2d
Novavax: Creating tomorrow’s vaccines today
Founded in 1987 in the US, Gale Smith – VP of vaccine development at Novavax – invented the technique of using insect cells for producing recombinant protein vaccines. A further milestone came ...
ImmunityBio’s (IBRX) Buy Rating Reiterated at D. Boral Capital
D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a report released on Friday,Benzinga reports. They currently have a $30.00 price target on the stock.
The First In China! BLA Submitted For Luzhu Biotech's Recombinant Herpes Zoster Vaccine Expected To Be Launched In 2026
The First in China! BLA Submitted for Luzhu Biotech's Recombinant Herpes Zoster Vaccine Expected to Be Launched in 2026 HONG KONG ...
Medscape6d
Recent Approaches in Hantavirus Vaccine Development
A variety of vaccine approaches, however, have been investigated using both inactivated virus and recombinant DNA technology. These approaches will be further discussed later in this review.
Vaccine Technologies Market to Reach $90.6 billion, Globally, by 2033 at 6.4% CAGR: Allied Market Research
The growth of the vaccine technologies market is driven by rise in prevalence of infectious diseases, growing trend towards preventive healthcare, and government immunization programs and initiatives.